Navigation Links
United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
Date:10/27/2011

SILVER SPRING, Md., Oct. 27, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2011.

"We achieved over $200 million in revenues this quarter, which reflects the continued strength of our core business," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "I'm also pleased that our Board of Directors recently authorized a $300 million share repurchase program, which has already begun to return additional value to our shareholders."

Total revenues for the quarter ended September 30, 2011 were $201.7 million, up from $168.6 million for the quarter ended September 30, 2010. Net income for the quarter ended September 30, 2011 was $84.4 million or $1.45 per basic share, compared to $39.7 million or $0.70 per basic share for the same quarter in 2010. Gross margin from sales was $178.3 million for the quarter ended September 30, 2011, compared to $148.1 million for the same quarter last year. Earnings before non-cash charges(1) for the quarter ended September 30, 2011 were $100.8 million, compared to $99.3 million for the quarter ended September 30, 2010.

Financial Results for the Three Months Ended September 30, 2011Revenues

The table below summarizes the components of net revenues (dollars in thousands):Three Months EndedSeptember 30,20112010PercentageChangeCardiopulmonary products:Remodulin

$

114,918$

109,5844.9%Tyvaso

66,33048,71736.2%Adcirca

19,7729,93599.0%Other

722339113.0%Total net revenues

$

201,742$

168,57519.7%Revenues for the quarter ended September 30, 2011 increased by $33.2 million, compared to the quarter ended September 30, 2010. The growth in revenues primarily reflects the increase in the number of patients being prescribed our produc
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. United States Holds Global Lead in Breast Cancer Research Publications as China Surges to Forefront, According to Report
2. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
3. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
4. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
5. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
6. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
7. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
8. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
9. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
10. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
11. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 Offering a complete line ... Entris Balance promotion . The Sartorius Entris Balance is ... high accuracy, and easy-to-maintain balance entry level balance. , ... was designed to help customer’s bridge the gap between ... that is very durable. Sartorius is the second biggest ...
(Date:11/21/2014)... November 20, 2014 The ... Chassis, Oligos, Enzymes, Cloning kits), Technology (Bioinformatics, ... (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast ... market drivers, threats, opportunities, and challenges. , ... figures spread through 185 pages and in-depth ...
(Date:11/21/2014)... 21, 2014 Why did Stephen Hawking ... Einstein so instantly recognizable? Why have they become icons ... and author Hilton Ratcliffe seeks out the answers to ... all to do with science. In " Stephen Hawking ... November 21, 2014), Ratcliffe puts it plainly: , ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... Wis. - Wisconsin's biobased industries could become a model ... are made, government and industry officials said at a leadership ... a summit to discuss Wisconsin's forest and agricultural industry and ... issues affecting expansion. Representatives from the U.S. Department of ...
... Being part of the more than 18,000 people who ... has not only become a worldwide phenomenon but its also becoming ... how rock n roll became mainstream in the 1960s. Though most ... on the Sunday night Ed Sullivan Show was a statement that ...
... What are you doing to become a better husband or ... not trying to turn my e-mail into a confessional. I've ... to folks who have been making that relationship work, it's ... and acceptance. Sounds like some idealized family. , ,"Oh great!" ...
Cached Biology Technology:Wisconsins biobased industries could be world leader 2Wisconsins biobased industries could be world leader 3Biotech phenomenon becoming mainstream in world economy 2Biotech phenomenon becoming mainstream in world economy 3Biotech phenomenon becoming mainstream in world economy 4Biotech phenomenon becoming mainstream in world economy 5Taking your work home 2Taking your work home 3
(Date:11/4/2014)... of Medicine announced today that it is a ... the Bill & Melinda Gates Foundation. Laura ... Reproductive Sciences; and Vice Chair of Research and ... will pursue an innovative global health and development ... Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals ...
(Date:11/4/2014)... 4, 2014   ...   Fuel3D , a developer of 3D ... round totaling $6.4 million (£4 million). This funding builds on ... this year and paves the way for the commercial launch ... The funding round was led by Chimera Partners and will ...
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... leaders do not immediately engage in a race against time ... not survive the global warming and acidification predicted for later ... marine scientists from around the world in a major new ... vital that the public understands that the lack of sustainability ...
... the winners of its student travel award to attend ... International Biophysics Congress in Long Beach, California, February 2-6, ... based on scientific merit, with priority given to those ... Each awardee receives a travel grant and will be ...
... Ore. December 21, 2007. In the early 1990s, federal ... Forest Plan. Part of that task involved an inventory ... to be associated with old-growth forests. Debates arose among the ... how best to carry it out. The recently published Conservation ...
Cached Biology News:Major study concludes that global warming is killing off coral 2Biophysical Society announces winners of 2008 Student Travel Awards 2Biophysical Society announces winners of 2008 Student Travel Awards 3Biophysical Society announces winners of 2008 Student Travel Awards 4Biophysical Society announces winners of 2008 Student Travel Awards 5
Rabbit anti-NFkB p105/p50 (Ser529) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
... Rabbit polyclonal to Taura Syndrome ... for all tested applications). ... Synthetic peptide: VTNSEGSTIL MNDIPITNQN VVLSKNVTDN ... corresponding to N terminal amino ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: